Filing Details

Accession Number:
0001181431-11-018429
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-03-16 16:14:28
Reporting Period:
2011-03-15
Filing Date:
2011-03-16
Accepted Time:
2011-03-16 16:14:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1070336 Achillion Pharmaceuticals Inc ACHN Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1378586 Gautam Shah C/O Achillion Pharmaceuticals
300 George Street
New Haven CT 06511
Svp And Chief Compliance Ofc. No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-03-15 5,000 $1.05 8,125 No 4 M Direct
Common Stock Disposition 2011-03-15 5,000 $5.94 3,125 No 4 S Direct
Common Stock Acquisiton 2011-03-16 2,726 $1.05 5,851 No 4 M Direct
Common Stock Disposition 2011-03-16 2,726 $6.11 3,125 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Buy) Disposition 2011-03-15 5,000 $0.00 5,000 $1.05
Common Stock Employee Stock Option (Right to Buy) Disposition 2011-03-16 2,726 $0.00 2,726 $1.05
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
11,742 2018-12-15 No 4 M Direct
9,016 2018-12-15 No 4 M Direct
Footnotes
  1. The price in column 4 is a weighted average price. The actual sale prices for these transactions ranged from $5.76 to 6.09. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
  2. This option was granted on December 15, 2008 and vests over a four year period with 25% of the shares vesting on the first anniversary of the date of grant and an additional 6.25% vesting at the end of each three-month period thereafter.